Apnimed.png
American Journal of Respiratory and Critical Care Medicine Publishes Full, Positive Results of Apnimed’s MARIPOSA Study on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea
October 10, 2023 08:30 ET | Apnimed, Inc.
CAMBRIDGE, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Apnimed.png
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors
October 02, 2023 08:00 ET | Apnimed, Inc.
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors
PRO3-420-A ProSomnus, Inc Logo_horizontal.png
ProSomnus Raises $10 Million To Fuel Growth and Optimize Operations
September 21, 2023 08:30 ET | ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), today announced...
Apnimed.png
Apnimed Announces First Patient Dosed in LunAIRo, the First Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
September 21, 2023 05:30 ET | Apnimed, Inc.
-- LunAIRo Compares AD109 to Placebo Over 6 and 12 Months in People with OSA who Are Intolerant of or Refuse Positive Airway Pressure (PAP) Therapy, the Current Standard of Care -- -- Second...
Apnimed.png
Apnimed to Present New Data on Investigational Oral Therapies for Obstructive Sleep Apnea at ERS International Congress 2023
September 06, 2023 08:00 ET | Apnimed, Inc.
-- New Post-Hoc Analysis of MARIPOSA Data on Estimating OSA Endotypes from theOxyhemoglobin Saturation Signal in Patients Dosed with AD109 for 1 Month -- Exploratory Trial on the Impact of...
Apnimed.png
Fierce Biotech Names Apnimed a 2023 “Fierce 15” Biotech Company
August 28, 2023 06:00 ET | Apnimed, Inc.
CAMBRIDGE, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Apnimed.png
APNIMED to Participate in the 43rd Annual Canaccord Genuity Global Growth Conference
August 01, 2023 08:00 ET | Apnimed, Inc.
CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
TIP_link_300x300.jpg
Sleep Apnea Devices Market Size to Reach $8.30 Billion at 7.9% CAGR with Home Healthcare Segment Driving Growth by 2025 | Report by The Insight Partners
July 26, 2023 05:52 ET | The Insight Partners
Pune, India, July 26, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners latest study on “Sleep Apnea Devices Market Size Report & Share Forecast to 2025 – COVID-19 Impact and Global...
ihl_logo.png
Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea
July 21, 2023 09:09 ET | Incannex Healthcare
MELBOURNE, Australia, July 21, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique...
ihl_logo.png
Incannex engages Fortrea to Manage its FDA IND Opening Phase 2/3 Clinical Trial Investigating IHL-42X for Treatment of Obstructive Sleep Apnoea
July 18, 2023 07:40 ET | Incannex Healthcare
Highlights: Incannex has engaged Fortrea as the contract research organisation (‘CRO’) to manage the IND opening Phase 2/3 clinical trial investigating IHL-42X for treatment of OSA.The Phase 2/3...